America’s overdose epidemic has been characterized as 4 distinct and interrelated epidemics: prescription opioids, heroin, fentanyl and fentanyl analogues, and stimulants. Even though physicians have decreased prescribing of opioid analgesics, America’s patients are currently facing a drug overdose – both fatal and non-fatal – epidemic that is fueled by illicit drugs, including counterfeit fentanyl and fentanyl analogues, psychostimulants, heroin, cocaine, and drug combinations.
The AMA and Manatt Health 2022 State Toolkit identifies more than 400 state laws, regulations, policy guidance and other select national actions being implemented to help end the nation's drug overdose epidemic. We encourage all states to use this resource as a go-to guide to increase access to evidence-based treatment and save lives from overdose.Learn More
Sharp reductions in prescription opioid supply, continued increases in PDMP use, but staggering increase in fatalities involving illicit opioids, methamphetamine, heroin and cocaine were demonstrated last year. AMA calls on policymakers and others to remove barriers to evidence-based care for patients with pain and those with a substance use disorder.Learn More
The nation’s drug-related overdose and death epidemic has changed and worsened. As a result, the AMA has united the Opioid and Pain Care Task Forces in a new, collective effort – the AMA Substance Use and Pain Care Task Force – to increase the urgency for evidence-based solutions.Explore
The AMA offers high-quality resources related to the use of data to shift from “response” to “prevention” of overdose, stigma, and educational opportunities for physicians and other medical professionals who seek to stay current and continuously improve the care they provide.Explore
Physicians demonstrate leadership every day in their practice to help patients with pain and those with a substance use disorder. These are a few of their stories.
AMA calls on policymakers and others to remove barriers to evidence-based care for patients with pain and those with a substance use disorder.Read more >
There is no legal, medical or policy reason to deny access to medications for opioid use disorder (MOUD) for justice-involved persons, according to leading medical, legal and health policy experts speaking on recentRead more >